Topical Agent Found To Kill Papillomavirus

February 12, 1999

HERSHEY, PA--A common surfactant and detergent found in many shampoos and toothpastes is the first topical microbicidal agent shown to kill animal and human papillomavirus, according to a Penn State researcher. Sodium dodecyl sulfate (SDS) was found in cell culture and animal testing to inactivate sexually transmitted viruses including human immunodeficiency virus (HIV), herpes simplex virus type 2 (HSV-2) and human papillomaviruses (HPVs). These viruses cause AIDS, genital herpes and genital warts, respectively.

"This is a major step toward our goal of producing a practical, non-toxic, inexpensive, discreet product which women can apply topically to the vagina prior to intercourse -- a product which would protect them from HPV infection even during encounters with infected partners," explains Mary K. Howett, Ph.D., professor of microbiology and immunology at Penn State's College of Medicine. "In the case of previously infected women, this agent could prevent them from transmitting the virus to their partners. In addition, this agent could be used alone or with other currently available microbicides or spermicides to prevent HSV-2 and HIV transmission."

Howett and her colleagues' work titled, "A Broad-Spectrum Microbicide with Virucidal Activity against Sexually Transmitted Viruses," is published in the February issue of the journal Antimicrobial Agents and Chemotherapy.

Howett says it will take at least several years before such products will be produced for use in humans. However, she adds that such products could greatly reduce cervical cancer.

Protection from genital wart viruses is important to public health because lesions caused by these viruses can progress to cancer, most notably cancer of the uterine cervix. This cancer causes 5,000 deaths per year in women in the U.S. In the developing world, cervical cancer is the number one cause of cancer related deaths in women. Worldwide, 250,000 women die annually from this form of cancer. Prevention of HPV infection could prevent most of these cancers. HPV infection may also lead to other cancers in the ano-genital tracts of women and men. HPV is frequently associated with vulvar and anal cancers. Prevention from transmission could also protect men and women from development of these cancers.

It is thought that about one in four women are infected by these viruses in the genital tract, with 1 to 3 percent of women showing overt signs of clinical infection upon gynecologic examination. Although most infected people do not develop cancer, individuals with HPV worry about infecting their partners, suffer from physical repercussions including possible loss of fertility and fear the development of cancer. Many people with HPV infection are unaware that they are infected. HPV infections occur commonly in adolescents and in people during their reproductive years. Lesions caused by these viruses are worse in immunocompromised people such as those with AIDS.

Howett and her colleagues are searching for partners to develop products that incorporate these anti-papillomavirus agents, alone or in combination with other microbicides. One such partnership has been established with Dan Malamud, Ph.D., and investigators at Biosyn, Inc. in Philadelphia to include SDS in products containing C31G, another potent microbicide under development by Biosyn.

The findings presented in this paper result from joint research efforts by investigators in the Departments of Microbiology and Immunology and Pathology and the Jake Gittlen Cancer Research Institute at The Milton S. Hershey Medical Center of the Penn State College of Medicine in Hershey, Pa. and investigators in the Department of Biochemistry at the University of Pennsylvania School of Dental Medicine, and at Biosyn, Inc. in Philadelphia, Pa.

The work was performed through funding provided by a Program Project Grant that was awarded to Penn State, the University of Pennsylvania, Biosyn, Inc. and the University of North Carolina by the National Institute of Allergy and Infectious Diseases, and from support provided by the Jake Gittlen Cancer Research Institute.
-end-


Penn State

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.